Pelabresib anhydrous

A novel phase 1 trial is investigating the combination of tagraxofusp and pacritinib in patients with myelofibrosis who have failed or cannot receive JAK1/2 inhibitor therapy, targeting a significant unmet need in this population.

The JAK inhibitors therapeutic landscape shows robust growth with over 50 pharmaceutical companies developing 55+ pipeline candidates across various clinical stages.

Recent updates from the ASH 2024 meeting highlight advancements in ruxolitinib combinations for treating myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Key studies discussed include MANIFEST-2, bomedemstat, and RESTORE trials, showing promising results in spleen volume reduction, symptom improvement, and addressing cytopenias.

Novartis announces closure of MorphoSys facilities in the US and Germany, affecting 330 jobs, following its $2.9 billion acquisition of the German biotech company.

Error occurred while parsing the model response.